Corium publishes data supporting needle-free transdermal influenza vaccine
The study outlines how antigens were used in vivo administration with the MicroCor system. The immunization results were comparable to the regular intramuscular injection administered to other test subjects. Corium International Inc., a commercial-stage biopharmaceutical company that specializes in creating, manufacturing and selling specialty transdermal products, created MicroCor.
The data results from the study were published in a manuscript titled “Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs.” The preclinical study, which was conducted by Corium and Novartis Vaccines, demonstrates that MicroCor is compatible with cell culture-derived influenza vaccines. MicroCor may be the next-generation vaccine delivery system.
"There is a significant unmet need for improving influenza vaccine accessibility by providing easy to use and needle-free delivery systems," Bobby Singh, chief technology officer and vice president for R&D at Corium, said. "We believe that use of our MicroCor technology to deliver influenza vaccine could provide significant benefit through improved immunization outcomes and more convenient vaccine delivery based on the results of this study."